The latest issue of The Bioprocess Curator included a lot of interesting news about vaccines. In case you missed it, here's some of the top stories.

The FDA has approved just three biosimilars in 2021 – but the approvals could shake up the field as discussions around interchangeability intensify.

The efforts of CDMOs have been absolutely crucial in the pandemic response. We ask five CDMO gurus how they reacted to COVID-19.

Part 2 of our roundtable discussion with CDMOs covers outsourcing preferences, the demand for mRNA, and more.

In this video interview, Mike Rea explains why each drug needs its own launch strategy.

After nine months of speculation about who will be the next FDA commissioner, we may finally be close to a decision.

The way the pharma industry has traditionally handled clinical trials does not make participation easy.

How is the field of antibody drug conjugates being reshaped?

Could mRNA vaccine be the flu interventions of tomorrow?

Pfizer-BioNTech COVID-19 vaccine receives full FDA approval.